340
57. Moorthy B, Miller KP, Jiang W, Ramos KS. The atherogen 3-methylcholanthrene induces
multiple DNA adducts in mouse aortic smooth muscle cells: role of cytochrome P4501B1.
Cardiovasc Res. 2002;53(4):1002–9.
58. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metabol.
2004;89(6):2548–56.
59. Heindel JJ, Schug TT. The obesogen hypothesis: current status and implications for human
health. Curr Environ Health Rep. 2014;1(4):333–40.
60. Janesick AS, Blumberg B. Obesogens: an emerging threat to public health. Am J Obstet
Gynecol. 2016;214(5):559–65.
61. Nappi F, Barrea L, Di Somma C, Savanelli M, Muscogiuri G, Orio F, et al. Endocrine aspects
of environmental “obesogen” pollutants. Int J Environ Res Public Health. 2016;13(8):765.
62. Grün F, Blumberg B. Environmental obesogens: organotins and endocrine disruption via
nuclear receptor signaling. Endocrinology. 2006;147(6):s50–s5.
63. Heindel JJ, Vom Saal FS, Blumberg B, Bovolin P, Calamandrei G, Ceresini G, et al. Parma
consensus statement on metabolic disruptors. Environ Health. 2015;14(1):54.
64. Janesick A, Blumberg B. Endocrine disrupting chemicals and the developmental programming
of adipogenesis and obesity. Birth Defects Res C Embryo Today. 2011;93(1):34–50.
65. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, et al. Dynamics
of fat cell turnover in humans. Nature. 2008;453(7196):783.
66. Darbre PD. Endocrine disruptors and obesity. Curr Obes Rep. 2017;6(1):18–27.
67. Sallis JF, Cervero RB, Ascher W, Henderson KA, Kraft MK, Kerr J. An ecological approach
to creating active living communities. Annu Rev Public Health. 2006;27:297–322.
68. Sallis JF, Glanz K. The role of built environments in physical activity, eating, and obesity in
childhood. Futur Child. 2006;16(1):89–108.
69. Sallis JF, Glanz K. Physical activity and food environments: solutions to the obesity epidemic.
Milbank Q. 2009;87(1):123–54.
70. Rundle A, Hoepner L, Hassoun A, Oberfield S, Freyer G, Holmes D, et al. Association of
childhood obesity with maternal exposure to ambient air polycyclic aromatic hydrocarbons
during pregnancy. Am J Epidemiol. 2012;175(11):1163–72.
71. Newbold RR, Padilla-Banks E, Jefferson WN, Heindel JJ. Effects of endocrine disruptors on
obesity. Int J Androl. 2008;31(2):201–8.
72. Cerniglia CE. Microbial metabolism of polycyclic aromatic hydrocarbons. In: Advances in
applied microbiology, vol. 30. Cambridge: Elsevier; 1984. p. 31–71.
73. Mueller JG, Cerniglia CE, Pritchard PH. Bioremediation of environments contaminated
by polycyclic aromatic hydrocarbons. In: Bioremediation principles and applications,
Biotechnology Research Series, vol. 6. Cambridge: Cambridge University Press; 1996.
p. 125–94.
74. Abdel-Shafy HI, Mansour MS. A review on polycyclic aromatic hydrocarbons: source, environmental impact, effect on human health and remediation. Egypt J Pet. 2016;25(1):107–23.
75. Santarelli RL, Pierre F, Corpet DE. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr Cancer. 2008;60(2):131–44.
76. Schnitz A, Squibb K, Oconnor J. Time-varying conjugation of 7, 12-dimethylbenz [a]
anthracene metabolites in rainbow trout (Oncorhynchus mykiss). Toxicol Appl Pharmacol.
1993;121(1):58–70.
77. Milo GE, Casto BC. Events of tumor progression associated with carcinogen treatment of epithelium and fibroblast compared with mutagenic events. In: Transformation of human epithelial cells: molecular and oncogenetic mechanisms. Boca Raton: CRC Press; 1992. p. 261–84.
78. Veraldi A, Costantini AS, Bolejack V, Miligi L, Vineis P, van Loveren H. Immunotoxic effects
of chemicals: a matrix for occupational and environmental epidemiological studies. Am J Ind
Med. 2006;49(12):1046–55.
79. Oostingh GJ, Schmittner M, Ehart AK, Tischler U, Duschl A. A high-throughput screening
method based on stably transformed human cells was used to determine the immunotoxic
effects of fluoranthene and other PAHs. Toxicol in Vitro. 2008;22(5):1301–10.
A. Khan et al.
57. Moorthy B, Miller KP, Jiang W, Ramos KS. The atherogen 3-methylcholanthrene induces
multiple DNA adducts in mouse aortic smooth muscle cells: role of cytochrome P4501B1.
Cardiovasc Res. 2002;53(4):1002–9.
58. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metabol.
2004;89(6):2548–56.
59. Heindel JJ, Schug TT. The obesogen hypothesis: current status and implications for human
health. Curr Environ Health Rep. 2014;1(4):333–40.
60. Janesick AS, Blumberg B. Obesogens: an emerging threat to public health. Am J Obstet
Gynecol. 2016;214(5):559–65.
61. Nappi F, Barrea L, Di Somma C, Savanelli M, Muscogiuri G, Orio F, et al. Endocrine aspects
of environmental “obesogen” pollutants. Int J Environ Res Public Health. 2016;13(8):765.
62. Grün F, Blumberg B. Environmental obesogens: organotins and endocrine disruption via
nuclear receptor signaling. Endocrinology. 2006;147(6):s50–s5.
63. Heindel JJ, Vom Saal FS, Blumberg B, Bovolin P, Calamandrei G, Ceresini G, et al. Parma
consensus statement on metabolic disruptors. Environ Health. 2015;14(1):54.
64. Janesick A, Blumberg B. Endocrine disrupting chemicals and the developmental programming
of adipogenesis and obesity. Birth Defects Res C Embryo Today. 2011;93(1):34–50.
65. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, et al. Dynamics
of fat cell turnover in humans. Nature. 2008;453(7196):783.
66. Darbre PD. Endocrine disruptors and obesity. Curr Obes Rep. 2017;6(1):18–27.
67. Sallis JF, Cervero RB, Ascher W, Henderson KA, Kraft MK, Kerr J. An ecological approach
to creating active living communities. Annu Rev Public Health. 2006;27:297–322.
68. Sallis JF, Glanz K. The role of built environments in physical activity, eating, and obesity in
childhood. Futur Child. 2006;16(1):89–108.
69. Sallis JF, Glanz K. Physical activity and food environments: solutions to the obesity epidemic.
Milbank Q. 2009;87(1):123–54.
70. Rundle A, Hoepner L, Hassoun A, Oberfield S, Freyer G, Holmes D, et al. Association of
childhood obesity with maternal exposure to ambient air polycyclic aromatic hydrocarbons
during pregnancy. Am J Epidemiol. 2012;175(11):1163–72.
71. Newbold RR, Padilla-Banks E, Jefferson WN, Heindel JJ. Effects of endocrine disruptors on
obesity. Int J Androl. 2008;31(2):201–8.
72. Cerniglia CE. Microbial metabolism of polycyclic aromatic hydrocarbons. In: Advances in
applied microbiology, vol. 30. Cambridge: Elsevier; 1984. p. 31–71.
73. Mueller JG, Cerniglia CE, Pritchard PH. Bioremediation of environments contaminated
by polycyclic aromatic hydrocarbons. In: Bioremediation principles and applications,
Biotechnology Research Series, vol. 6. Cambridge: Cambridge University Press; 1996.
p. 125–94.
74. Abdel-Shafy HI, Mansour MS. A review on polycyclic aromatic hydrocarbons: source, environmental impact, effect on human health and remediation. Egypt J Pet. 2016;25(1):107–23.
75. Santarelli RL, Pierre F, Corpet DE. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. Nutr Cancer. 2008;60(2):131–44.
76. Schnitz A, Squibb K, Oconnor J. Time-varying conjugation of 7, 12-dimethylbenz [a]
anthracene metabolites in rainbow trout (Oncorhynchus mykiss). Toxicol Appl Pharmacol.
1993;121(1):58–70.
77. Milo GE, Casto BC. Events of tumor progression associated with carcinogen treatment of epithelium and fibroblast compared with mutagenic events. In: Transformation of human epithelial cells: molecular and oncogenetic mechanisms. Boca Raton: CRC Press; 1992. p. 261–84.
78. Veraldi A, Costantini AS, Bolejack V, Miligi L, Vineis P, van Loveren H. Immunotoxic effects
of chemicals: a matrix for occupational and environmental epidemiological studies. Am J Ind
Med. 2006;49(12):1046–55.
79. Oostingh GJ, Schmittner M, Ehart AK, Tischler U, Duschl A. A high-throughput screening
method based on stably transformed human cells was used to determine the immunotoxic
effects of fluoranthene and other PAHs. Toxicol in Vitro. 2008;22(5):1301–10.
A. Khan et al.